67
Diamond Score
ADMA Biologics, Inc.
Healthcare · Biotechnology · $2.5B market cap
Overlooked
Strong Foundation
$10.49
Updated 2026-04-11
Discovery Thesis
AI-generated catalyst thesis will be available after transcript analysis. The quantitative signals below highlight why this company appears to be at an inflection point.
Quantitative summary: Margin expanding 3Q, PEG 0.55, deleveraging.
Three-Pillar Score Breakdown
Valuation
✦ Reasonably Priced
ADMA trades at a PEG of 0.55 — paying below the typical price for its growth rate.
Inflection Signals
Revenue Acceleration
4Q data
QoQ growth: -0.0234 → 0.0626 → 0.1003 → 0.0368
Margin Expansion
3Q streak
Margins: 0.3038 → 0.3508 → 0.3801 → 0.4509
ROIC Trend
9.0%
0.0612 → 0.0754 → 0.0758 → 0.0901
Insider Buying
2 buys (90d)
PEG Ratio
0.55
Below 1.0 — undervalued relative to growth
Debt Paydown
D/E 0.167
0.22 → 0.21 → 0.193 → 0.167
Relative Strength (6M)
-33.3%
Insider Buying Activity (Last 90 Days)
-
ELMS STEVE
— director
-
ELMS STEVE
— director
Earnings Surprise Streak
2026-02-25
+8.1%
$0.2 vs $0.185
Foundation — Business Quality
Revenue Growth (YoY)
19.6%
Overlooked — Why the Market Hasn't Noticed
Analyst Coverage
1 analyst
Very low coverage
Market Cap
$2.5B
Sweet spot ($2-10B)
ETF Inclusion
Not in top ETFs